Back to Rankings

ANL

Adlai NortyeD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
View Chart
Current thesis
The bullish case is that the market is valuing ANL mainly as a damaged post-BURAN shell even though the company has now funded itself with a $140.0 million PIPE [#PR-2026-02-03], started AN9025 Phase 1 [#PR-2026-02-12], and still guides AN4035 toward mid-2026 IND [#6K-2025-12-29]. If AN9025 shows credible early clinical signals, the current market cap could look too low for a funded multi-asset oncology platform.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +20.7.
What can break
AN4035 IND timing could slip beyond mid-2026, weakening the backup pipeline narrative.
Momentum
75
Value
41
Sentiment
31
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $11.00 · Bull $16.00 · Bear $6.50
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $28.50
Why
Momentum75 · Δ7d +20.7
Value41 · Δ7d +0.1
Sentiment31 · Δ7d -30.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
75
26% active weight
Current posture
7d trendSoftening
Δ7d
+20.7
Δ21d
+29.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
31
34% active weight
Current posture
7d trendSoftening
Δ7d
-30.0
Δ21d
-8.1
Why this grade

Composite grade D. Momentum 74.8 / Value 41.1 / Sentiment 31.2

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$479.2M
Beta
-
Shares Out
34.34M
P/E (TTM) · Derived
-12.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-11.54
Rev YoY
-
EPS YoY
+45.7%
Gross Margin
-
Op Margin
-1293.4%
Net Debt
$2.59M
Current Ratio
0.65
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology